Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
, 96 (34), e7708

Histological Improvement of Liver Fibrosis in Well-Treated Patients With Autoimmune Hepatitis: A Cohort Study

Observational Study

Histological Improvement of Liver Fibrosis in Well-Treated Patients With Autoimmune Hepatitis: A Cohort Study

Åsa D Borssén et al. Medicine (Baltimore).


Autoimmune hepatitis (AIH) is a chronic autoimmune liver disease that if left untreated may lead to the development of cirrhosis. Previous studies on AIH patients have suggested that fibrosis and even cirrhosis can be reversed by medical treatment. The aim of this study was to evaluate the efficacy of medical treatment for protection of developing fibrosis and cirrhosis.A total of 258 liver biopsies from 101 patients (72 women, 29 men) were analyzed by a single pathologist and classified according to the Ishak grading (inflammation) and staging (fibrosis) system. Liver histology was stratified according to the temporal changes of fibrosis stage (increased, decreased, or stable), and groups were compared.Complete or partial response to medical treatment was 94.9%. Reduction of fibrosis stage from the first to the last biopsy was seen in 63 patients (62.4%). We found an association between a reduction in the fibrosis stage and continuous glucocorticoid medication, as well as lowered scores of inflammation at last biopsy. Twenty-one patients had cirrhosis (Ishak stage 6) at least in one of the previous biopsies, but only 5 patients at the last biopsy.Histological improvement is common in AIH patients that respond to medical treatment, and a reduction or stabilization of fibrosis stage occurs in about 2/3 of such patients.

Conflict of interest statement

The remaining authors have no conflicts of interest to disclose.


Figure 1
Figure 1
Flow chart of the inclusion of biopsies.
Figure 2
Figure 2
Fibrosis stage in 258 biopsies from 101 AIH patients, sorted by year after diagnosis. AIH = autoimmune hepatitis.

Similar articles

See all similar articles

Cited by 2 articles


    1. EASL Clinical Practice Guidelines. Autoimmune hepatitis. J Hepatol 2015;63:971–1004. - PubMed
    1. Gleeson D, Heneghan MA. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011;60:1611–29. - PubMed
    1. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193–213. - PubMed
    1. Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008;43:1232–40. - PubMed
    1. Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42:53–62. - PubMed

Publication types